Pancreatic Cancer Research

ResearcherCalifornia Institute of TechnologyActive in the last 2 years

Xiang Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6647-0684; OpenAlex author ID A5001461011. Sources: OpenAlex.

Their work

Papers
6 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 3 papers

Papers 6

  1. KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. First author DOI 10.1002/advs.202504886↗
  2. Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING Agonist Plus Mutant KRAS mRNA. First author DOI 10.1021/acsnano.4c14102↗
  3. Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies. Last author DOI 10.1021/acsnano.5c14753↗
  4. Correction to "Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-imm… First author DOI 10.1021/acsnano.3c06667↗
  5. Use of Stromal Intervention and Exogenous Neoantigen Vaccination to Boost Pancreatic Cancer Chemo-Immunotherapy by Nanocarriers. Co-author DOI 10.3390/bioengineering10101205↗
  6. Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. First author DOI 10.1021/acsnano.2c06300↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. André E. Nel · 6 shared papers, 2022–2025 · strength 1.76
  2. Lijia Luo · 5 shared papers, 2022–2025 · strength 1.50
  3. Xiao Xu · 1 shared paper, 2025 · strength 0.33
  4. Saborni Chattopadhyay · 1 shared paper, 2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.